



CIRRUSDX

FINAL

Accession #: LAC2026-000025

Name: Doe, Jane

DOB: 2/2/1987

MRN/SSN:

Sex: Female

Laboratory Information	Sample Information	Practice Information
CirrusDx, Inc 77 Upper Rock Circle, 4 th Floor Rockville, MD 20850 CLIA# 21D2130541 Dr. Todd Myers, Lab Director 240-813-8801 or reports@cirrusdx.com	Technician: CWS Date Collected: 6/24/2026 Date Received: 6/25/2026 Date Reported: 6/25/2026 Reporting Method: Email	Name: Apple Urogynocology Provider: Winesap MD, Roma Address: 123 Apple Way Farmville MD 12345 Phone: 987-654-3210 Fax: 987-654-1230 Email: results@appleurology.com

Testing Information		
Test Name: <i>Lactobacillus</i> Panel (LacP™)	Test Method: Real-Time PCR (Molecular)	Specimen Type: Vaginal Swab

Pathogen	Result	Detection Level (Organism/mL)
<i>L. acidophilus</i>	Not Detected	N/A
<i>L. casei</i> / <i>L. paracasei</i>	Not Detected	N/A
<i>L. crispatus</i>	Detected	1x10 ⁸
<i>L. fermentum</i> / <i>L. delbreukii</i> / <i>L. plantarum</i>	Not Detected	N/A
<i>L. gasseri</i> / <i>L. paragasseri</i>	Not Detected	N/A
<i>L. helveticus</i> / <i>L. brevis</i> / <i>L. vaginalis</i>	Not Detected	N/A
<i>L. iners</i>	Not Detected	N/A
<i>L. jensennii</i> / <i>L. mulieris</i>	Not Detected	N/A
<i>L. reuteri</i>	Not Detected	N/A
<i>L. rhamnosus</i>	Detected	1x10 ⁶

General Comments
None.

Notes:

Questions including Clinical Consultation on Results: 240-813-8801 or clinicaladvocates@cirrusdx.com

Organisms Tested (Reference Range): *L. acidophilus* (< 1x10⁴), *L. casei* / *L. paracasei* (< 1x10⁴), *L. crispatus* (< 1x10⁴), *L. fermentum* / *L. delbreukii* / *L. plantarum* (< 1x10⁴), *L. gasseri* / *L. paragasseri* (< 1x10⁴), *L. helveticus* / *L. brevis* / *L. vaginalis* (< 1x10⁴), *L. iners* (< 1x10⁴), *L. jensennii* / *L. mulieris* (< 1x10⁴), *L. reuteri* (< 1x10⁴), *L. rhamnosus* (< 1x10⁴)

Organisms/mL: are based on the calculation of genome equivalents. One genome equivalent is theoretically equal to one colony forming unit (cfu).

It is the physician's responsibility to interpret the results provided and determine the appropriate (if any) treatment options.

This molecular test was developed and its performance characteristics were determined by CirrusDx. They have not been cleared or approved by the US Food and Drug Administration. The FDA does not require it to go through premarket FDA review. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing.

This report has been reviewed and approved by: 

F-322.00

Dr. Todd Myers, Laboratory Director.